Use of generic drugs is promoted in Peru

Home/Policies & Legislation | Posted 23/07/2021 post-comment0 Post your comment

To promote the use of generic medicines in Peru, on 31 October 2019, the Executive Branch published regulations through Supreme Decree No. 026-2019-SA, which established mechanisms to ensure access to lower-cost medicines. The decree recognizes the need to adopt measures that favour the population’s access to essential medicines, biological products, and medical devices.

41 AA008899

Peru’s Ministry of Health (MINSA) is responsible for leading the National and Decentralized Health System, the policy for universal health insurance and the intersectoral policies and actions on social determinants.

As of 6 March 2020, failure to comply with the Government's provisions would result in the application of the scale of infringements and penalties to pharmacies and apothecaries for not keeping available the dispensing of generic essential medicines from the list approved by MINSA.

By law, this could range from a non-monetary reprimand to the payment of two Tax Units (Unidades Impositivas Tributarias, UIT) (S/8,600). MINSA's National Center for the Supply of Strategic Health Resources (Cenares) will be responsible for the follow-up, monitoring and evaluation of compliance with the law.

These establishments must also keep available for dispensing or dispensing the complete treatment regimens for each of the listed medicines.

The list is composed of 31 medicines for respiratory ailments, diabetes, hypertension, mental health, fungal infections, among others. It also indicates the (mg/mL) that the product should have, as well as the presentation (tablet, syrup or inhaler as in the case of salbutamol).

These are generic drugs with an International Nonproprietary Name (INN), that is without a brand name, contained in the Single National Formulary of Essential Medicines (Petitorio Nacional Único de Medicamentos Esenciale, Pnume). Among them are amitriptyline, amoxicillin, azithromycin, clonazepam, enalaptril, fluconazole, ibuprofen, loratadine, naproxen, paracetamol, prednisone and omeprazole.

Recently an agreement was established between the Municipality of San Borja and the DIRIS Lima Centro which means that this department of the Ministry of Health oversees the supply of generic medicines, in agreement with Pnume. This is an example of how a joint effort with local governments can bring more people into the health system.

Editor’s comment
Readers interested to learn more about the use of generics in other countries are invited to visit to view the following manuscript published in GaBI Journal:

‘To prescribe generics is to play with the life of the patient’: misconceptions of generics in Guatemala

GaBI Journal is indexed in Embase, Scopus, Emerging Sources Citation Index and more.

Readers interested in contributing a research or perspective paper in Spanish and/or English on the use of generics to GaBI Journal – an independent, peer reviewed academic journal – please submit your manuscript here.

GaBI Journal Citation Impact
1.9 – CiteScore 2020 (calculated on 5 May 2021)
1.7 – CiteScoreTracker 2021 (Last updated on 4 July 2021)

Submit a manuscript to GaBI Journal

Related articles
GPhA comments on generics’ legislation and Trans-Pacific Partnership

Access to generic medicines undermined in free trade agreement


The brand-new section the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. 

View this week’s headline article: ¿Qué conduce a las percepciones negativas de los biosimilares?

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.


Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: ¿Qué conduce a las percepciones negativas de los biosimilares?

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

Source: MINSA

comment icon Comments (0)
Post your comment
Related content
PDUFA VI: FDA could promote generics competition
47 MD001813
Home/Policies & Legislation Posted 29/07/2022
House bill passes FDA funding fees but conflicts with Senate bill
User Fee V13H23
Home/Policies & Legislation Posted 15/07/2022
US Senate clarifies status of interchangeable biosimilar exclusivity
Interchangeability V18K30
Home/Policies & Legislation Posted 27/05/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010